Abstract

Hepatocellular carcinoma (HCC) is the third most common malignant tumor of the digestive system. Plasma cell tumor heterotopic gene 1 (PVT1) is an intergenic long non-coding RNA that is aberrantly expressed in different cancers. Myocardin-related transcription factor A or megakaryoblastic leukemia 1 (MKL1) is a transcriptional coactivator of serum response factor that has been shown to promote cancer cell migration and invasion. In this study, we investigated the relationship between PVT1 and MKL1 as a novel regulatory mechanism underlying HCC progression. We used HepG2 and Cos-7 cell lines. Transfection experiments with miR-3619-5p mimics/inhibitor, PVT1, siRNA-PVT1, MKL1, or siRNA-MKL1 were performed. RNA and protein levels were analyzed by quantitative reverse transcription PCR and Western blot, respectively. Cell migration was assessed by transwell assay. Luciferase assays, RNA-FISH, RNA immunoprecipitation, and chromatin immunoprecipitation assays were performed to confirm the interaction between PVT1, miR-3619-5p, and MKL1 in HCC cells. Overexpression of PVT1 was positively correlated with MKL1 upregulation, which promoted HepG2 cell migration. miR-3619-5p inhibited MKL1 expression in HCC cells by acting on its 3′-UTR. Furthermore, PVT1 promoted MKL1 expression and migration in HCC cells by directly binding to miR-3619-5p. In a positive feedback loop, MKL1 could activate PVT1 transcription by binding to the CArG box in the promoter region. Our findings may provide a basis for the development of novel targeted therapies in HCC.

Highlights

  • Hepatocellular carcinoma (HCC) gradually became one of the most common cancers and the second leading risk around the world [1]

  • QRT-PCR and Western blot were used to reveal the potential relationship between PVT1 and megakaryoblastic leukemia 1 (MKL1)

  • The data showed that the expression of MKL1 was upregulated when PVT1 was overexpressed

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) gradually became one of the most common cancers and the second leading risk around the world [1]. Most HCC patients eventually die due to tumor metastasis-associated deaths [2]. Today, screening novel biomarkers for developing effective therapeutic targets against the metastasis of HCC may make up for the shortcomings of current therapeutic strategies. Human plasma cell tumor heterotopic gene 1 (PVT1) belongs to intergenic gene long non-coding RNAs (lncRNAs). Submitted: 08 February 2020/Accepted: 22 February 2020

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call